A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: cruelty (1), gravity (15)

Capecitabine-Trastuzumab-SC-Tucatinib

Description
Chemotherapy Protocol BREAST CANCER Capecitabine– Trastuzumab (SC)-Tucatinib Regimen • Breast Cancer – Capecitabine–Trastuzumab (SC)-Tucatinib Indication • Tr
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Capecitabine-Trastuzumab-SC-Tucatinib.pdf

Inotuzumab Ozogamicin

Description
Relapsed or refractory CD22-positive B-Cell acute lymphoblastic leukaemia.
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/ALL/Inotuzumab-Ozogamicin.pdf

Carotid endarterectomy - patient information

Description
Information about having a carotid endarterectomy
Url
/Media/UHS-website-2019/Patientinformation/Cardiovascular-and-thoracic/Carotid-endarterectomy-1656-PIL.pdf

Endometrial-Dostarlimab

Description
Chemotherapy Protocol GYNACOLOGICAL CANCER Dostarlimab Regimen  Endometrial - Dostarlimab Indication  Dostarlimab is in
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/Dostarlimab.pdf

Avelumab(800mg)

Description
Chemotherapy Protocol BLADDER CANCER AVELUMAB (800mg) Regimen  Bladder Cancer - Avelumab Indication  Avelumab is indicated as monotherapy for the firs
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Avelumab800mg.pdf

Carfilzomib-Dexamethasone(20) Ver1

Description
Chemotherapy Protocol MYELOMA Carfilzomib-Dexamethasone (20) Regimen • Myeloma – Carfilzomib-Dexamethasone (20) Indication • Carfilzomib in combination with dexamethas
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/carfilzomib-dexamethasone20-ver1.pdf

Carfilzomib(14 day)-Dexamethasone(20) Ver1

Description
Chemotherapy Protocol MYELOMA Carfilzomib (14 day)-Dexamethasone (20) Regimen  Myeloma – Carfilzomib-Dexamethasone (20) Indication  Carfilzomib
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/carfilzomib14-day-dexamethasone20-ver1.pdf

Durvalumab_14day

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (14 day) Regimen • NSCLC - Durvalumab (14 day) Indication • Stage 3 NSCLC a
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab-14day.pdf

Durvalumab(28day-1500mg)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (28 day – 1500mg) Regimen • NSCLC - Durvalumab (28 day – 1500mg) Indication
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab28day-1500mg.pdf

Atezolizumab1680mg

Description
Chemotherapy Protocol LUNG CANCER Atezolizumab (1680mg 28 days) Regimen • Lung – Atezolizumab Indication • Atezolizumab is indica
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Atezolizumab1680mg.pdf
101 to 110 of 156
Previous … 9 10 11 12 13 … Next